App-Quantinova.ai

Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease

Paul Ellis - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Alpha-1 antitrypsin (A1AT) deficiency

Alpha 1-Antitrypsin

Characteristics and treatment patterns of newly diagnosed COPD patients in Canada

Nafeesa Dhalwani - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Targeted Retreatment of Incompletely Resolved COPD Exacerbations With Ciprofloxacin

Andrew Ritchie - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Ciprofloxacin

Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials

Roland Buhl - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Tiotropium/olodaterol

How common is stepping-down asthma treatment in England?

Chloe Bloom - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

Theophylline

Evaluation of the steroid sparing effects of Mepolizumab using the Glucocorticoid Toxicity Index

Pamela Jane McDowell - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Glucocorticoid

Interval Exercise Training in Poorly Controlled Asthma: Preliminary Clinical Trial Results

Anna Freeman - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Self-administration of mepolizumab via an autoinjector: the patient experience

Lee Evitt - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Mepolizumab

Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?

Grainne dAncona - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Health care resource utilization (HCRU) in early and late diagnosed Chronic Obstructive Pulmonary Disease (COPD) patients in UK primary care

Konstantinos Kostikas - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Are COPD patients taking triple combination inhalers being overmedicated during acute exacerbations?

Angela Moran - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Patient pathway modelling using Discrete Event Simulation to reduce readmissions in COPD

Usame Yakutcan - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

The impact and quality outcomes of a community based COPD annual review service

Emma Rickards - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

The relationship between severe asthma eosinophilic phenotypes and the clinical response to benralizumab at 16 weeks

David Jackson - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Benralizumab

Durability of mepolizumab treatment response between doses

Ian Douglas Pavord - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Mepolizumab

Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease

Rhamiya Mahendran - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Resveratrol

Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial

Claus Vogelmeier - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Umeclidinium

The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints

MeiLan K. Han - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD

Maria Polyzoi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Formoterol/glycopyrrolate

Effect of azithromycin treatment on inflammation in COPD patients

Rassin Lababidi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Azithromycin

Filters

45280 Abstracts